Key Points
- CEO Eran Ophir sold 5,000 shares on April 24 at $3.20 under a pre-arranged Rule 10b5-1 plan, trimming his stake to 11,375 shares (a 30.53% reduction); he sold a total of 15,625 shares in April for roughly $42,931 in proceeds.
- Compugen reported a strong quarter on March 2 with EPS of $0.60 (vs. $0.05 expected) and revenue of $67.33M (vs. $14.3M expected), but analysts still forecast a fiscal-year EPS of -0.26; the stock trades near $2.92 with a market cap of about $276M and a 52-week range of $1.23–$3.23.
Compugen Ltd. (NASDAQ:CGEN - Get Free Report) CEO Eran Ophir sold 5,000 shares of the stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of $3.20, for a total transaction of $16,000.00. Following the completion of the sale, the chief executive officer directly owned 11,375 shares of the company's stock, valued at $36,400. This trade represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eran Ophir also recently made the following trade(s):
- On Tuesday, April 14th, Eran Ophir sold 5,000 shares of Compugen stock. The stock was sold at an average price of $2.90, for a total value of $14,500.00.
- On Wednesday, April 1st, Eran Ophir sold 5,625 shares of Compugen stock. The shares were sold at an average price of $2.21, for a total transaction of $12,431.25.
Compugen Stock Down 5.8%
Shares of NASDAQ CGEN opened at $2.92 on Tuesday. Compugen Ltd. has a fifty-two week low of $1.23 and a fifty-two week high of $3.23. The firm's 50-day simple moving average is $2.26 and its 200 day simple moving average is $1.91. The stock has a market cap of $276.09 million, a P/E ratio of 7.89 and a beta of 2.77.
Compugen (NASDAQ:CGEN - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.55. Compugen had a net margin of 48.57% and a return on equity of 55.68%. The business had revenue of $67.33 million for the quarter, compared to analysts' expectations of $14.30 million. On average, sell-side analysts anticipate that Compugen Ltd. will post -0.26 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently weighed in on CGEN. Lake Street Capital began coverage on shares of Compugen in a research note on Tuesday, April 7th. They set a "buy" rating and a $6.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Compugen in a research note on Monday, April 20th. Truist Financial upgraded shares of Compugen to a "strong-buy" rating in a research note on Wednesday, March 25th. Wall Street Zen upgraded shares of Compugen from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. Finally, HC Wainwright began coverage on Compugen in a report on Wednesday, January 7th. They set a "buy" rating and a $4.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Compugen currently has an average rating of "Moderate Buy" and an average target price of $5.00.
Check Out Our Latest Analysis on CGEN
Hedge Funds Weigh In On Compugen
Several large investors have recently made changes to their positions in the business. Bank Hapoalim BM purchased a new position in Compugen in the 4th quarter worth about $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in Compugen in the 4th quarter worth about $38,000. Franklin Resources Inc. purchased a new position in Compugen in the 2nd quarter worth about $56,000. Osaic Holdings Inc. increased its stake in Compugen by 346.0% in the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company's stock worth $78,000 after purchasing an additional 34,045 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Compugen in the 4th quarter worth about $84,000. Institutional investors own 12.22% of the company's stock.
Compugen Company Profile
(
Get Free Report)
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen's predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
